A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Poly ICLC (Primary) ; Melanoma vaccine
- Indications Malignant melanoma
- Focus Adverse reactions
- 06 Feb 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2017 According to a Neon Therapeutics media release, initial results from the study have been published in Nature.